Sorry, you need to enable JavaScript to visit this website.

Coronavirus COVID-19 Vaccine Updates

Our Path to Developing the Pfizer-BioNTech COVID-19 Vaccine

In the fight against COVID-19, a vaccine is a critical part of addressing the global health crisis by decreasing rates of infection, disease and death worldwide. Pfizer and BioNTech leveraged decades of scientific expertise to design and execute a rigorous Phase 3 clinical trial program to make the Pfizer-BioNTech COVID-19 Vaccine available as quickly and safely as possible. Today, we are continuing to evaluate data from this landmark trial, while also initiating new trials in special populations, such as pregnant women and children under 12. We are also planning studies to assess the potential need for boosters or modified vaccine in the event that newly emerging variants evade protection provided by the existing vaccine.

Developing the Pfizer-BioNTech COVID-19 vaccine is only possible through the dedicated work of thousands of individuals and those who volunteer to take part in research. We are grateful to all of our clinical trial investigators and their study teams who are partnering with us in this effort and to all of the participants and their families who have and will volunteer to help make a difference for society. Vaccine doses for placebo recipients in our studies have been secured. To date, all participants 16 years and older in our landmark trial have been offered the opportunity to receive the vaccine.

Related Articles

Learn more about progress on our path to develop a COVID-19 vaccine.


For additional information about Pfizer, please see our filings with the U.S. Securities and Exchange Commission, including the information provided in the sections captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”.